Our findings show that Low-dose IL-2 therapy might particularly benefit autoimmune disease patients with increased risk of infection due to compromised immunity, such as reduced CD8+ T cell function, but caution should be taken to avoid potential CD8+ T cell-mediated immunopathology. Here, CD8A is linked to autoimmune disease.